Targeting Gut Microbiota Metabolites to Prevent Liver Cancer
Targeting Gut Microbiota Metabolites to Prevent Liver Cancer
批准号:
10557785
负责人:
Rachel M. Golonka
金额:
$1.27万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-01-13 至 2023-01-14
关键词:
16S ribosomal RNA sequencingAbateAblationAcidsAllyAnhydridesAntibioticsAntitumor ResponseAttenuatedBAY 54-9085BackBacteriaBile AcidsBiological MarkersBreedingButyratesCancer BiologyCancer EtiologyCarcinomaCell SeparationCellsCessation of lifeChildhood Liver CancerCytotoxic T-LymphocytesDataDiagnosticDietDietary InterventionDiseaseDoctor of PhilosophyElderlyEnvironmental Risk FactorFiberFlow CytometryFosteringFutureG-Protein-Coupled ReceptorsGammaproteobacteriaGastrointestinal tract structureGeneticGoalsGrowthHepaticHepatocarcinogenesisHistone Deacetylase InhibitorHumanHumulusHydrolaseImmuneImmunologic SurveillanceImmunologicsImmunologyImmunosuppressionImmunotherapyImpairmentInterventionIntestinesInulinKnowledgeLaboratoriesLiteratureLiver neoplasmsMalignant neoplasm of liverMediatingMetagenomicsMicrobeModelingMonitorMusNatural ImmunityNatural Killer CellsNatureNutritional BiochemistryOralPathogenesisPatientsPhenotypePhysiologyPrimary carcinoma of the liver cellsProcessProductionPublicationsReactionRegimenRegulatory T-LymphocyteReportingRepressionResearchResistanceRoleSerumSeveritiesSurvival RateT-LymphocyteTechnical ExpertiseTherapeuticTherapeutic InterventionUnited StatesUnited States Department of AgricultureUniversitiesVolatile Fatty AcidsWild Type Mouseadaptive immunitybile saltsdehydroxylationdiagnostic tooldysbiosisfeedinggene therapygerm free conditiongut dysbiosisgut microbiotainhibitorinsightmalemetabolomicsmicrobial productsmicrobiotamicrobiota metabolitesmortalitymouse modelnew therapeutic targetnovelopportunistic pathogenpathogenic bacteriapharmacologicprebioticspreventreceptorside effecttherapeutic targettherapeutically effectivetranslational therapeuticstumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Hepatocellular carcinoma (HCC) has emerged as a leading cause of cancer-related
deaths globally and in the United States. Metagenomic studies are unveiling that gut
microbiota dysbiosis may possess diagnostic potential for HCC patients. Intriguingly, our
previous Cell publication highlights that a diet enriched with the fermentable fiber inulin
can act as the trigger to induce HCC in mice with preexisting gut dysbiosis. Ablation of
the gut microbiota through antibiotics and germ-free conditions completely eradicated
inulin-induced HCC, which leads to question HOW does the gut microbiota contribute to
HCC and, on the therapeutic standpoint, WHAT within the gut microbiota can be
specifically targeted to impede HCC. Accordingly, we first found this HCC phenotype in
genetically altered mice but for this proposal we have generated gut dysbiotic wild-type
(WTDYS) mice through extensive breeding and cross fostering to study specifically the role
of gut microbiota in inulin-induced HCC. Through 16S rRNA sequencing, we found that
WTDYS mice recapitulated the HCC-associated microbiota, which includes an overgrowth
of short chain fatty acid (SCFA)- and secondary bile acid (2° BA)-producing Clostridia
species and opportunistic pathogens like γ-Proteobacteria. While the fecal and serum
contents from WTDYS mice fed on inulin containing diet are in the process for
metabolomics analysis, we expect to have a striking elevation of SCFA and 2° BA based
on the associated bacterial blooms, which would be analogous to our original model with
genetic deficiency. Intriguingly, both gut metabolites have been recently delineated in the
literature to cause a severe reduction of invariant natural killer T (iNKT) cells but expand
regulatory T (Treg) cell abundance, which would downregulate anti-tumor responses and
favor immunosuppression, respectively. From this recent insight, we performed hepatic
immune cell isolation and characterization via flow cytometry in WTDYS mice and identified
mitigated levels of iNKT but overpopulated Treg cells. Our previous study and preliminary
data lead us to the central hypothesis that gut microbiota-dependent immunosuppression
is a main contributor to inulin-induced HCC. In Aim 1, we will implement pharmacologic
and genetic interventions to blockade SCFA production and activation of SCFA receptors,
while Aim 2 will apply pharmacologic and dietary interventions to inhibit 2° BA production,
which we posit will be two independent, but inter-related, approaches to abate inulin-
induced HCC by restoring anti-tumor immunosurveillance.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Targeting Gut Microbiota Metabolites to Prevent Liver Cancer
-
批准号:10386414
-
项目类别:
-
资助金额:$4.09万
-
财政年份:2022
-
负责人:Rachel M. Golonka
-
依托单位:
海外基金